{
    "abstract": "This study compared the risks of atherothrombotic major adverse cardiovascular events in patients with type 2 diabetes taking SGLT2 (sodium-glucose cotransporter 2) inhibitors to those taking DPP-4 (dipeptidyl peptidase-4) inhibitors.\nAll adult patients (\u226518\u2009years of age) with type 2 diabetes and newly prescribed with SGLT2 inhibitors or DPP-4 inhibitors across all public hospitals in Hong Kong between January 2015 and December 2019 were included. Patients were propensity matched in a 1:1 ratio using a caliper distance of 0.2 without replacement. The primary outcome was atherothrombotic major adverse cardiovascular events as a composite outcome of cardiovascular mortality, nonfatal stroke, and nonfatal myocardial infarction. Time-to-first event analysis was conducted using a univariable Cox proportional hazards model. Primary and secondary analyses were repeated using stabilized inverse probability weighting and propensity score adjustment in the complete case cohort. A total of 20\u2009642 patients (10\u2009321 SGLT2 inhibitors versus 10\u2009321 DPP-4 inhibitors) were included in the final analysis. The mean age was 59\u00b111\u2009years, and 13\u2009142 (63.7%) were men. The median follow-up period was 2.9\u2009years. The use of SGLT2 inhibitors was associated with a significant reduction in atherothrombotic major adverse cardiovascular events (453 [4.4%] versus 719 [7.0%]; hazard ratio, 0.64 [95% CI, 0.57-0.72]; \nSGLT2 inhibitors in patients with diabetes were independently associated with reduction in atherothrombotic major adverse cardiovascular events, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, and incident dialysis, compared with DPP-4 inhibitors.",
    "authors": [
        {
            "affiliation": "Department of Adult Intensive Care Queen Mary Hospital Hong Kong SAR China.\nCritical Care Medicine Unit, School of Clinical Medicine, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong SAR China.",
            "firstname": "Pauline Yeung",
            "initials": "PY",
            "lastname": "Ng"
        },
        {
            "affiliation": "Department of Medicine, Queen Mary Hospital The University of Hong Kong Hong Kong SAR China.",
            "firstname": "Andrew Kei-Yan",
            "initials": "AK",
            "lastname": "Ng"
        },
        {
            "affiliation": "Critical Care Medicine Unit, School of Clinical Medicine, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong SAR China.",
            "firstname": "April",
            "initials": "A",
            "lastname": "Ip"
        },
        {
            "affiliation": "Department of Adult Intensive Care Queen Mary Hospital Hong Kong SAR China.\nCritical Care Medicine Unit, School of Clinical Medicine, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong SAR China.",
            "firstname": "Wai Ching",
            "initials": "WC",
            "lastname": "Sin"
        },
        {
            "affiliation": "Department of Medicine, Queen Mary Hospital The University of Hong Kong Hong Kong SAR China.\nDivision of Cardiology, Department of Medicine The University of Hong Kong-Shenzhen Hospital Shen Zhen China.",
            "firstname": "Kai-Hang",
            "initials": "KH",
            "lastname": "Yiu"
        }
    ],
    "conclusions": null,
    "copyrights": null,
    "doi": "10.1161/JAHA.124.037207",
    "journal": "Journal of the American Heart Association",
    "keywords": [
        "DPP\u20104 inhibitor",
        "SGLT2 inhibitor",
        "cardiovascular mortality",
        "myocardial infarction",
        "type 2 diabetes"
    ],
    "methods": null,
    "publication_date": "2024-12-25",
    "pubmed_id": "39719404",
    "results": null,
    "title": "Atherothrombotic Outcomes After Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes: A Territory-Wide Retrospective Cohort Study.",
    "xml": "<Element 'PubmedArticle' at 0x788503f83ec0>"
}